Acura Pharma shareholders were not the least bit happy to hear the developer announce yesterday that it was unlikely the FDA will approve Acurox--which combines niacin and oxycodone--by a June 30 deadline. Its shares tanked on the news, plunging more than 30 percent. Acura did not offer a reason why it believes the FDA won't make its deadline. "It's a data and labelling issue. I don't think they have the data to have an appropriate label," Biologic Investment Research analyst Kevin McNamara told Reuters. Report